IL-2 in the treatment of chronic myeloid leukemia after lymphoid blast crisis: a pilot study
Meloni, G.; Foà, R.; Tosti, S.; Vignetti, M.; Gavosto, F.; Mandelli, F.
Haematologica 75(6): 502-505
1990
ISSN/ISBN: 0390-6078 PMID: 2098290 Document Number: 349383
Five patients with lymphoid blastic transformation of chronic myeloid leukemia have been treated with IL2 associated with Vincristine (VCR) plus Prednisone (PDN). Our study indicates that IL2 may be employed in the management of this disease without excessive toxicity at the higher doses in hospitalized patients and at the lower doses as outpatients. Concerning the therapeutic efficacy, our preliminary results indicate that IL2 might be useful in enhancing the chemosensitivity of the leukemic blasts. It remains to be seen if this will result in a rapid return to the CP and in a prolongation of survival.